Nu.q® vet cancer test launched in-clinic in u.s. and europe through antech

Henderson, nev. , april 23, 2024 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has announced that its nu.q® vet cancer test is now available in-clinic to veterinarians across the u.s and europe through antech, a leading veterinary diagnostics company.

VNRX Ratings Summary

VNRX Quant Ranking